Comparative Pharmacology
Head-to-head clinical analysis: ALEVE versus IBU.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALEVE versus IBU.
ALEVE vs IBU
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Naproxen, a nonsteroidal anti-inflammatory drug (NSAID), inhibits cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing prostaglandin synthesis. This leads to decreased inflammation, pain, and fever.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
220 mg orally every 8 to 12 hours as needed; maximum 660 mg per day.
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.
None Documented
None Documented
Terminal elimination half-life is 12-17 hours; allows twice-daily dosing for steady-state concentrations.
Clinical Note
moderateEribulin + Digoxin
"Eribulin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateEribulin + Digitoxin
"Eribulin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateEribulin + Deslanoside
"Eribulin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateEribulin + Acetyldigitoxin
"Eribulin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (30 hours) and elderly (up to 6 hours). No accumulation with recommended dosing due to short t½.
Renal (95% as unchanged drug and metabolites); biliary/fecal (5%)
Renal (90% as conjugated metabolites, 10% unchanged), biliary/fecal (minor, <5%)
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)